GlassScriptPhysician profile
Clifford Garvin
NPI 1528095502
$5,113.21
in general payments reported to CMS, 2019-2025
51 companies · $501 in 2025
The $501 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $697 · 2021: $915 · 2022: $652 · 2023: $653 · 2024: $874 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.62 | 2020-2025 | |
| Pfizer INC. | $619.22 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $431.28 | 2021-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $344.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $325.60 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $224.80 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $214.17 | 2019-2021 | |
| Lilly USA, LLC | $191.71 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.79 | 2020-2025 | Caplyta |
| Allergan, INC. | $185.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $167.47 | 2019-2025 | Airsupra, Farxiga |
| Avanir Pharmaceuticals, INC. | $104.47 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $90.86 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $88.04 | 2023-2024 | Gemtesa, Aptiom |
| Phathom Pharmaceuticals, INC. | $86.42 | 2024-2025 | Voquezna |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Garvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.